Navigation Links
Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
Date:8/26/2010

CHAPEL HILL, N.C., Aug. 26 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutic agents for the treatment of cardiovascular disease, today announced that it has initiated a dose-defining Phase IIa trial of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure (ADHF). ADHF is the leading diagnosis for patients at the time of discharge from U.S. hospitals and the most common cause of hospitalization for patients over 65 years of age.(i)

"Following the significant clinical results from our recently completed Phase I/IIa dose escalation study demonstrating CXL-1020's attractive hemodynamic and safety profile, we are excited to continue to evaluate this important new therapy for patients with ADHF," said Chris Kroeger, M.D., Cardioxyl Pharmaceuticals President and Chief Executive Officer. "We believe that CXL-1020 is the only cardiovascular product in development that provides the ideal balance of blood vessel dilation combined with direct enhancement of cardiac diastolic and systolic function."

Cardioxyl's placebo-controlled, multi-center Phase IIa study is designed to further define a suitable clinical dosage for CXL-1020, and is being conducted at up to 20 U.S. and international clinical sites. This three-cohort study will enroll 54 to 66 cardiac patients with decompensated heart failure.  Hemodynamic parameters are being evaluated during intravenous infusion of CXL-1020 at several dose levels. Investigators will assess hemodynamics utilizing invasive and non-invasive techniques including both echocardiography and direct Swan-Ganz catheter-based measures of heart pressures and function.  The primary efficacy endpoints for this study include an evaluation of dose-related hemodynamic effects. The study will also expand the d
'/>"/>

SOURCE Cardioxyl Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lotus Pharmaceuticals Enter R-Bambuterol(R) Clinical Trial I
2. Jiangbo Pharmaceuticals Chairman to Ring NASDAQ Opening Bell on August 27, 2010
3. Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI® (epoprostenol for injection) for Pulmonary Arterial Hypertension
4. China Yongxin Pharmaceuticals Reports Second Quarter 2010 Results
5. Jazz Pharmaceuticals Provides Update on FDA Advisory Committee Meeting For JZP-6 (Sodium Oxybate) in Fibromyalgia
6. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
7. Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
8. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
9. Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
10. Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million
11. Trubion Pharmaceuticals Inc. Reports Second-Quarter and First-Half 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... corporate update and report second quarter 2014 financial results ... August 1, 2014. That same day, Arena will host ... Time (5:30 a.m. Pacific Time). The ... domestic callers and 914.495.8552 for international callers. Please specify ...
(Date:7/24/2014)... , July 24, 2014  PTC Therapeutics, Inc. ... Company will host a webcast conference call to report ... update on the company,s business and outlook on Thursday, ... opening of the market. The call ... (973) 935-8152 (international) five minutes prior to the start ...
(Date:7/24/2014)... 24, 2014  Uroplasty, Inc. (NASDAQ: UPI ... and markets innovative proprietary products to treat voiding ... 2015 first quarter ended June 30, 2014.  ... Neuromodulation System grew 19% to $4.1 million, as ... of the prior year.  Total revenue for the ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... Australia, March 12, 2007: Progen Industries Limited,(ASX: PGL; NASDAQ: ... liver cancer data has been accepted for late breaking ... the Liver,(EASL). Progen will also be presenting the results ... Cancer Research (AACR),Annual Meeting 2007. , ,In expectation ...
... - Tyrima Demonstrates Good Safety Profile and Excellent,Pharmacokinetic ... 2007 /PRNewswire/ --,CeNeRx BioPharma, Inc., a clinical stage ... the central,nervous system, today announced top-line results from ... candidate for the treatment,of depression and anxiety. In ...
Cached Medicine Technology:PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3
(Date:7/25/2014)... 2014 Reproductive Science Center (RSC) of ... Kerri Luzzo, Lead Physician at RSC Rhode Island, received ... accomplishments in fertility care and community outreach issued by ... Annual PBN Awards ceremony held July 24th at Salve ... most highly regarded, emerging leaders in their field were ...
(Date:7/25/2014)... 25, 2014 Florida Hospital and MOSI officially ... organizations for years to come and make a difference in ... $2 million dollar check to provide the support needed to ... enable MOSI to transform the IMAX Dome Theatre from film ... the only IMAX Dome Theatre in the state of Florida, ...
(Date:7/25/2014)... -- The human brain can preserve oxygen to protect ... finds. Although dehydration significantly reduces blood flow ... the brain compensates by increasing the amount of oxygen ... helped us understand a lot more about how the ... study first author Steven Trangmar, a researcher at Brunel ...
(Date:7/25/2014)... San Diego, CA (PRWEB) July 25, 2014 ... regarding all the latest information from the FDA on ... on July 21, that one lot of Ibuprofen and one ... recalled due to mislabeled packaging. Oxcarbazepine is used ... with epilepsy. , The reason for the recall ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... revealed that 39 percent of all children in the survey ... , The survey looked at 2,505 children during the years of ... four years of age. The final result was that about ... care. Many of these children were from lower-income families and were ...
Breaking Medicine News(10 mins):Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3
... to rid the brain of the amyloid buildup that plagues ... the method outlined in a paper published online August 12 ... Center show how the bodys natural way of ridding the ... disease. Then the team demonstrated an experimental method in mice ...
... 2007 UT Southwestern Medical Center researchers have discovered ... the human cardiovascular system, including lowering the elevated heart ... ,We have found that cocaines effects on the ... a drug called dexmedetomidine, which is currently approved by ...
... Food and Drug Administration (FDA) Nanotechnology Task Force is ... effort to tackle the new scientific and regulatory challenges ... clear and candid in acknowledging the pervasive potential of ... pharmaceuticals and devices to cosmetics and food supplements— and ...
... drug that stimulates the growth of infection-fighting white blood ... a chemotherapy-related complication characterized by fever and low white ... by researchers from the University of Rochester School of ... Center. , "Chemotherapy drugs target cancer cells, but ...
... scientists said Monday that they have further evidence to suggest ... would make a promising target for new drugs to ... first identified the enzyme, protein kinase G (PknG), as a ... time, they said that the protein is the secret weapon ...
... created from an egg matured in a laboratory, frozen, thawed ... a medical conference on Monday. ,The baby ... disease, and three other women in the 20-person trial group ... ,Doctors already collect and store eggs from women who face ...
Cached Medicine News:Health News:Draining away brain's toxic protein to stop Alzheimer's 2Health News:Draining away brain's toxic protein to stop Alzheimer's 3Health News:New treatment effective in counteracting cocaine-induced symptoms 2Health News:White Blood Cell Booster May Help Cancer Patients Avoid Deadly Complications 2Health News:Structure of TB Enzyme Points the Way to New Drugs: Study 2Health News:Infertility Breakthrough With First Birth from Lab-matured Egg 2Health News:Infertility Breakthrough With First Birth from Lab-matured Egg 3
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
Inquire...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... Hamilton is precision, ergonomics, and ... hand fatigue with soft non-slip, contoured ... with smooth, light plunger spring action ... and sterilization without the need for ...
Medicine Products: